Drug discovery of PD-L1 inhibitor Atezolizumab
DOI:
https://doi.org/10.54097/hset.v8i.1253Keywords:
Atezolizumab, PD-L1.Abstract
Immunotherapy, especially immune checkpoint inhibitors have made a tremendous breakthrough in NSCLC management. Over last decades, ICIs targeting the PD-1, PD-L1 and CTLA-4 have exhibited promising antitumor efficacy and durable response including NSCLC patients with advanced or refractory, metastatic disease. We will provide an overview of mechanism of cancer development and how current available ICIs can be employed to improve patients’ outcome. This review also summarized the discovery process of atezolizumab which led to final FDA approval for its indication. Our major focus is on the significant survival benefit achieved by atezolizumab and taking into consideration of its advantages and disadvantages when we applied it into clinical setting. We hope to help patients and clinicians to better understand the mechanisms, clinical progress and future research direction of NSCLC atezolizumab in decision making.
Downloads
References
Fernando C. Santini & Charles M. Rudin (2017): Atezolizumab for the treatment of non-small cell lung cancer, Expert Review of Clinical Pharmacology, DOI: 10.1080/17512433.2017.1356717.
US Food and Drug Administration. (2017). FDA approves first treatment for rare form of skin cancer.
Kim, E. S. Avelumab: first global approval. Drugs, 2017, pp. 929 - 937.
"Imfinzi- durvalumab injection, solution". DailyMed. 5 June 2020. Retrieved 30 September 2020.
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., ... & Özgüroğlu, M. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. New England Journal of Medicine, 2017, pp. 1919 - 1929.
Herbst, R. S., Gordon, M. S., Fine, G. D., Sosman, J. A., Soria, J. C., Hamid, O., ... & Hodi, F. S. (2013). A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
Santini, F. C., & Rudin, C. M. Atezolizumab for the treatment of non-small cell lung cancer. Expert review of clinical pharmacology, 2017, pp. 935 - 945.
Deng, R., Bumbaca, D., Pastuskovas, C. V., Boswell, C. A., West, D., Cowan, K. J., ... & Iyer, S. (2016, April). Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. In MAbs (Vol. 8, No. 3, pp. 593-603). Taylor & Francis.
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Frontiers in pharmacology, 2017, p. 561.
Weinstock, C., Khozin, S., Suzman, D., Zhang, L., Tang, S., Wahby, S., ... & Pazdur, R. US Food and Drug Administration approval summary: atezolizumab for metastatic non–small cell lung cancer. Clinical Cancer Research, 2017, pp. 4534 - 4539.
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., Van Der Heijden, M. S., Balar, A. V., Necchi, A., ... & Dreicer, R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet, 2016, pp. 1909 - 1920.
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for immunotherapy of cancer, 2018, pp. 1 - 18.
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., ... & McDermott, D. F. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nature communications, 2016, pp. 1 - 8.
Dhillon, S., & Syed, Y. Y. Atezolizumab first-line combination therapy: a review in metastatic nonsquamous NSCLC. Targeted oncology, 2019, pp. 759 - 768.
Criss, S. D., Mooradian, M. J., Watson, T. R., Gainor, J. F., Reynolds, K. L., & Kong, C. Y. Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non–small cell lung cancer in the United States. JAMA network open, 2019, pp. e1911952-e1911952.
Kang, C., & Syed, Y. Y. Atezolizumab (in combination with nab-paclitaxel): a review in advanced triple-negative breast cancer. Drugs, 2020, pp. 601 - 607.
Schmid, P., Loirat, D., Savas, P., Espinosa, E., Boni, V., Italiano, A., ... & Sablin, M. (2019). Abstract CT049: Phase Ib study evaluating a triple combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC).
Pal, S. K., Agarwal, N., Loriot, Y., Suarez Rodriguez, C., Singh, P., Vaishampayan, U. N., ... & Necchi, A. (2020). Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
